Long-term major adverse liver outcomes in 1,260 patients with non-cirrhotic NAFLD.

Journal: JHEP reports : innovation in hepatology
Published Date: Sep 25, 2023

Abstract

BACKGROUND & AIMS: Long-term studies of the prognosis of NAFLD are scarce. Here, we investigated the risk of major adverse liver outcomes (MALO) in a large cohort of patients with NAFLD.

Authors

  • Camilla Akbari
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Maja Dodd
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Per Stål
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Patrik Nasr
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Mattias Ekstedt
    Division of Internal Medicine, Department of Gastroenterology and Hepatology and Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden.
  • Stergios Kechagias
    Division of Internal Medicine, Department of Gastroenterology and Hepatology and Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden.
  • Johan Vessby
    Department of Medical Sciences, Gastroenterology Research Group, Uppsala University Hospital, Uppsala, Sweden.
  • Fredrik Rorsman
    Department of Medical Sciences, Gastroenterology Research Group, Uppsala University Hospital, Uppsala, Sweden.
  • Xiao Zhang
    Merck & Co., Inc., Rahway, NJ, USA.
  • Tongtong Wang
    Merck & Co., Inc., Rahway, NJ, USA.
  • Thomas Jemielita
    Merck & Co., Inc., Rahway, NJ, USA.
  • Gail Fernandes
    Merck & Co., Inc., Rahway, NJ, USA.
  • Samuel S Engel
    Merck & Co., Inc., Rahway, NJ, USA.
  • Hannes Hagström
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Ying Shang
    Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals